New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 30, 2013
08:29 EDTALNYAlnylam completes ALN-TTR02 Phase II trial enrollment
Alnylam Pharmaceuticals announced that it has completed enrollment in its Phase II trial with ALN-TTR02. Recent interim results from this Phase II study showed that ALN-TTR02 achieved up to 93% knockdown of TTR, the disease-causing protein in ATTR. ALN-TTR02 activity was found to be rapid, dose dependent, and durable, with similar levels of TTR knockdown observed toward both wild-type and mutant protein. In addition, ALN-TTR02 was found to be generally safe and well tolerated in this study. Alnylam also announced today that its open-label extension study with ALN-TTR02 is open for enrollment. The OLE study will evaluate the long-term safety and tolerability of ALN-TTR02 and will also measure effects of treatment toward a number of clinical endpoints, including a Neuropathy Impairment Score, or “NIS.” The company intends to report clinical data from this study about once per year, with initial data in 2014.
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
08:01 EDTALNYAlnylam announces planned departure of Chief Business Officer
Subscribe for More Information
December 18, 2014
08:09 EDTALNYAlnylam names Cubist CEO Michael Bonney to board of directors
Subscribe for More Information
December 15, 2014
08:42 EDTALNYAlnylam price target raised to $125 from $105 at Leerink
Subscribe for More Information
06:06 EDTALNYAlnylam price target raised to $158 from $134 at Piper Jaffray
Subscribe for More Information
December 12, 2014
10:01 EDTALNYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:05 EDTALNYAlnylam sees filing IND for ALN-HBV DC program in late 2015
Subscribe for More Information
07:03 EDTALNYAlnylam sees initial data from ALN-PCSsc trial in mid-2015
Subscribe for More Information
07:02 EDTALNYAlnylam updates guidance to file clinical trial application for ALN-AS1
Subscribe for More Information
05:30 EDTALNYAlnylam initiated with a Neutral at Goldman
Goldman started shares of Alnylam Pharmaceuticals with a Neutral rating and $113 price target saying it prefers to wait for a more favorable entry point into the name.
December 11, 2014
16:02 EDTALNYAlnylam initiates ENDEAVOUR Phase 3 clinical trial with revusiran
Subscribe for More Information
08:02 EDTALNYAlnylam, The Medicines Co. announce initiation of Phase 1 ALN-PCSsc trial
Subscribe for More Information
December 9, 2014
12:22 EDTALNYPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
06:38 EDTALNYAlnylam to host conference call
Conference call to discuss Phase 1 data from ALN-AT3, in development for the treatment of hemophilia will be held on December 9 at 8 am. Webcast Link
05:47 EDTALNYAlnylam reports poisitve initial results for ALN-AT3
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use